Neurizon Therapeutics (ASX:NUZ) Receives FDA Feedback on HEALEY ALS Trial Pathway

Aditi Sarkar

06 October 2026 01:52 PM AEDT

Neurizon Therapeutics (ASX:NUZ) Receives FDA Feedback on HEALEY ALS Trial Pathway

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FDA indicated positive HEALEY results could support traditional approval of NUZ-001.
Trial may serve as the single registrational study for an NDA, subject to evidence requirements.
Topline results from HEALEY Regimen I anticipated in late Q2 2027.
NIH-funded expanded access program for about 200 patients expected to begin in Q1 2027.

Neurizon Therapeutics Limited (ASX:NUZ) has received written feedback from the US Food and Drug Administration following a Type C meeting request regarding NUZ-001, its investigational treatment for amyotrophic lateral sclerosis (ALS). The feedback provides guidance on the regulatory pathway and clinical development strategy.

Potential Registrational Pathway

The FDA confirmed that positive results from the HEALEY ALS Platform Trial could support traditional approval for NUZ-001. The trial may serve as the single registrational study for a New Drug Application (NDA), subject to meeting the requirement for substantial evidence of effectiveness.

CEO Dr Chris Bremer said the feedback gives the company valuable guidance as it prepares the evidence package for the NDA.

Biomarker Strategy and Fast Track

The FDA endorsed measuring plasma neurofilament light chain (NfL) as a marker of nerve damage, while noting that substantial scientific rationale would be needed if the trial's primary endpoint is not met. Neurizon intends NfL data to form part of the supporting evidence for traditional approval rather than accelerated approval.

Following the FDA's January 2026 decision not to grant Fast Track Designation, the agency indicated the company may resubmit based on available data. Neurizon is evaluating this option.

Trial Timeline and Expanded Access

HEALEY Regimen I remains fully enrolled, with topline results anticipated in late Q2 2027.

A NIH-funded expanded access program involving approximately 200 ALS patients is expected to begin in Q1 2027, providing up to 96 weeks of treatment access while generating additional safety and biomarker data.

Key Takeaways

FDA feedback indicates HEALEY could be the single registrational study for NUZ-001, subject to evidence standards.
NfL biomarker data will support the traditional approval pathway.
Topline trial results are expected in late Q2 2027, with expanded access from Q1 2027.

FAQs

Q: What is NUZ-001?

A:NUZ-001 is Neurizon's investigational treatment for amyotrophic lateral sclerosis (ALS).

Q: What did the FDA indicate?

A:The FDA indicated positive HEALEY trial results could support traditional approval and serve as a single registrational study.

Q: What role will NfL play?

A:Plasma NfL data is intended to form part of the supporting evidence for traditional approval.

Q: When are HEALEY topline results expected?

A:Topline results from HEALEY Regimen I are anticipated in late Q2 2027.

Q: What is the expanded access program?

A:A NIH-funded program for about 200 ALS patients, expected to start in Q1 2027, offering up to 96 weeks of treatment.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.